Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Comparison of FRETS-VWF73 to full-length VWF as a substrate for ADAMTS13 activity measurement in human plasma samples.

Mahdian R, Rayes J, Girma JP, Houllier A, Obert B, Meyer D, Veyradier A.

Thromb Haemost. 2006 Jun;95(6):1049-51. No abstract available.

PMID:
16732393
2.

FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.

Mancini I, Valsecchi C, Lotta LA, Deforche L, Pontiggia S, Bajetta M, Palla R, Vanhoorelbeke K, Peyvandi F.

Thromb Haemost. 2014 Aug;112(2):297-303. doi: 10.1160/TH13-08-0688. Epub 2014 Apr 17.

PMID:
24740645
3.

Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement.

Joly B, Stepanian A, Hajage D, Thouzeau S, Capdenat S, Coppo P, Veyradier A.

Thromb Res. 2014 Nov;134(5):1074-80. doi: 10.1016/j.thromres.2014.09.006. Epub 2014 Sep 16.

PMID:
25262108
4.

Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods.

Kremer Hovinga JA, Mottini M, Lämmle B.

J Thromb Haemost. 2006 May;4(5):1146-8. No abstract available.

5.

Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.

Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL.

Blood. 2009 Aug 20;114(8):1666-74. doi: 10.1182/blood-2009-01-195461. Epub 2009 Jun 18.

6.

Mechanistic studies on ADAMTS13 catalysis.

Di Stasio E, Lancellotti S, Peyvandi F, Palla R, Mannucci PM, De Cristofaro R.

Biophys J. 2008 Sep;95(5):2450-61. doi: 10.1529/biophysj.108.131532. Epub 2008 May 23.

7.

Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS.

Thromb Haemost. 2007 Sep;98(3):593-9.

PMID:
17849048
8.

FRETS-VWF73: a rapid and predictive tool for thrombotic thrombocytopenic purpura.

Groot E, Hulstein JJ, Rison CN, de Groot PG, Fijnheer R.

J Thromb Haemost. 2006 Mar;4(3):698-9. No abstract available.

9.

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B.

N Engl J Med. 1998 Nov 26;339(22):1578-84.

10.

FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T.

Br J Haematol. 2005 Apr;129(1):93-100.

PMID:
15801961
11.

[Expression of vWF73 and VWF114 fragments of von Willebrand factor A2 domain and their utilization in detecting ADAMTS13 activity].

Zhang JY, Ma ZN, Dong NZ, Hu LP, Su J, Wang ZY, Ruan CG.

Zhonghua Xue Ye Xue Za Zhi. 2011 May;32(5):337-41. Chinese.

PMID:
21729605
12.

[Development and application of a new ADAMTS13 assay for TTP diagnosis].

Kokame K, Miyata T.

Rinsho Byori. 2005 Jul;53(7):639-45. Review. Japanese.

PMID:
16104533
13.

The WXXW motif in the TSR1 of ADAMTS13 is important for its secretion and proteolytic activity.

Ling J, Su J, Ma Z, Ruan C.

Thromb Res. 2013 Jun;131(6):529-34. doi: 10.1016/j.thromres.2013.04.024. Epub 2013 May 14.

PMID:
23683325
14.

Zinc and calcium ions cooperatively modulate ADAMTS13 activity.

Anderson PJ, Kokame K, Sadler JE.

J Biol Chem. 2006 Jan 13;281(2):850-7. Epub 2005 Nov 11.

16.

An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.

Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE.

J Thromb Haemost. 2013 Aug;11(8):1511-8. doi: 10.1111/jth.12319.

17.

VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13.

Kokame K, Matsumoto M, Fujimura Y, Miyata T.

Blood. 2004 Jan 15;103(2):607-12. Epub 2003 Sep 25.

18.

von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.

Remuzzi G, Galbusera M, Noris M, Canciani MT, Daina E, Bresin E, Contaretti S, Caprioli J, Gamba S, Ruggenenti P, Perico N, Mannucci PM; Italian Registry of Recurrent and Familial HUS/TTP. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.

Blood. 2002 Aug 1;100(3):778-85.

19.

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.

Molvarec A, Rigó J Jr, Bõze T, Derzsy Z, Cervenak L, Makó V, Gombos T, Udvardy ML, Hársfalvi J, Prohászka Z.

Thromb Haemost. 2009 Feb;101(2):305-11.

PMID:
19190814
20.

Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor.

Varadi K, Rottensteiner H, Vejda S, Weber A, Muchitsch EM, Turecek PL, Ehrlich HJ, Scheiflinger F, Schwarz HP.

J Thromb Haemost. 2009 Jul;7(7):1134-42. doi: 10.1111/j.1538-7836.2009.03453.x. Epub 2009 Apr 24.

Supplemental Content

Support Center